Perception of the quality of life of families and patients with severe Haemophilia A in prophylactic treatment with Emicizumab or FVIII lyophilisate: Focus group study

被引：0
|
作者：
Gonzalez Ruiz, Lina [1 ]
Zuniga Contreras, Pamela [1 ]
Rosas, Amaia [1 ]
Nielsen Guzman, Benjamin [1 ]
机构：
[1] Pontificia Univ Catolica Chile, Santiago, Region Metropol, Chile
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
Haemophilia patients must face challenges that impact their quality of life; There are no quality-of-life scales for patients receiving new therapies; When receiving treatment with Emicizumab they have a common experience of 'new normal life';
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FP-006 (14
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [1] Prophylactic Treatment of Severe Haemophilia A Patients with Inhibitors to FVIII with Peglip-FVIII
    Timofeeva, Margarita
    Zozulya, Nadezhda I.
    Pospelova, Tatiana
    Kosinova, Marina V.
    Kurtov, Igor
    Tuddenham, Edward
    Ling, Gavin
    BLOOD, 2021, 138
  • [2] Prophylactic Treatment of Severe Haemophilia a Patients with Inhibitors to FVIII with Peglip-FVIII
    Tuddenham, Edward
    Wolf-Garraway, Richard
    Ling, Gavin
    BLOOD, 2022, 140 : 5617 - 5618
  • [3] Emicizumab improves thrombin generation and quality of life compared to previous FVIII prophylaxis in haemophilia a patients
    Marco-Rico, A.
    Marco-Vera, P.
    HAEMOPHILIA, 2024, 30 : 58 - 59
  • [4] PATIENTS' QUALITY OF LIFE AND CLINICAL OUTCOMES OF EMICIZUMAB PROPHYLAXIS THERAPY FOR THE SEVERE HAEMOPHILIA A TREATMENT IN CHINA
    Bao, H.
    Lin, Z.
    Lin, A.
    Ran, X.
    Xia, Y.
    Buhrer, C.
    Jovanoski, N.
    Xuan, J.
    VALUE IN HEALTH, 2022, 25 (01) : S228 - S228
  • [5] Quality of life assessment and pharmacokinetic study in haemophilia A patients undergoing prophylactic treatment
    Kotsiou, N.
    Gavriilaki, E.
    Chissan, S.
    Ntova, Z.
    Moka, E.
    Aivazidou, S.
    Katsetsiadis, A.
    Kalmoukos, P.
    Vakalopoulou, S.
    HAEMOPHILIA, 2024, 30 : 109 - 110
  • [6] Long-term analysis of real clinical practice of emicizumab treatment in patients with severe haemophilia A with and without FVIII inhibitors
    Zozulya, N.
    Dimitrieva, O.
    Yakovleva, E.
    HAEMOPHILIA, 2024, 30 : 122 - 122
  • [7] Quality of life and joint health modifications in severe haemophilia A patients switching to an Emicizumab prophylaxis regimen
    Trillo, Alyson
    Fraga, Kelli
    Bastos, Maria
    Davis, Joanna
    Corrales-Medina, Fernando
    HAEMOPHILIA, 2022, 28 : 70 - 71
  • [8] Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy
    Oka, Gaelle
    Roussel-Robert, Valerie
    Levivien, Clara
    Lopez, Isabelle
    Pieragostini, Remi
    HAEMOPHILIA, 2023, 29 (03) : 709 - 715
  • [9] Early changes in bleeding perception and quality of life in children and adolescents receiving emicizumab prophylaxis for severe haemophilia A without inhibitor
    Falaise, Celine
    Roche, Martine
    Gensollen, Sophie
    Hezard, Nathalie
    Boucekine, Mohamed
    Auquier, Pascal
    Chambost, Herve
    Saultier, Paul
    HAEMOPHILIA, 2023, 29 (01) : 397 - 400
  • [10] On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients
    Mikovic, D.
    Woodhams, B. J.
    Holmstrom, M.
    Elezovic, I.
    Antovic, A.
    Mobarrez, F.
    Elfvinge, P.
    Antovic, J. P.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2012, 34 (01) : 35 - 40
12345